US Department of Health and Human Services. 65+ in the United States. 2005. http://www.census.gov/prod/2006pubs/p23-209.pdf
Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6(suppl 9):S3-S10. Abstract
Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds. Campbell’s Urology. 8th ed. Philadelphia, PA: WB Saunders Co; 2002:1297-1336.
Roehrborn CG. Int J Impot Res. 2008;20(suppl 3):S11-S18. Abstract
Kirby RS, Gilling PJ. Fast Facts: Benign Prostatic Hyperplasia. Oxford, United Kingdom: Health Press; 1995.
Barry M, Fowler FJ, O'Leary MP, et al; The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549-1557. Abstract
Oishi K, Boyle P, Barry JM, et al. Epidemiology and natural history of benign prostatic hyperplasia. In: Denis L, Griffiths K, Khoury S, et al, eds. Fourth International Consultation on BPH, Paris, July 1997; Plymouth, UK: Health Publications; 1998:25-59.
McConnell JD. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, Number 8. AHCPR Publication No. 94-0582. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, February 1994.
Resnick M, Ackermann R, Bosch J, et al. Initial evaluation of LUTS. In: Chatelain C et al, eds. Benign Prostatic Hyperplasia. Plymouth, UK: Health Publication Ltd; 2001:167-188.
Speakman MJ. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): More than treating symptoms? Eur Urol. 2008;7(suppl):680-689.
Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol. 2006;49:651-659. Abstract
Thorner DA, Weiss JP. Benign prostatic hyperplasia: Symptoms, symptom scores, and outcome measures. Urol Clin North Am. 2009;36:417-429 Abstract
Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95:87-100. Abstract
Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009;103(suppl 3):12-23. Abstract
Knutson T, Edlund C, Fall M, Dahlstrand C. BPH with coexisting overactive bladder dysfunction -- an everyday urological dilemma. Neurourol Urodyn. 2001;20:237-247. Abstract
Helfand BT, Manvar A, Fought AJ, et al. Recalled AUA-SI and QOL scores do not accurately predict a patient’s previous lower urinary tract symptoms (LUTS) in the outpatient setting. J Urol. 2009;181(4 suppl):702. Abstract 1942.
Abrams P. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009;181:1779-1787. Abstract
Reproduced with permission, www.cartoonstock.com
Girman CJ, Panser LA, Chute CG, et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol. 1993;150:887-892. Abstract
Wikipedia Digital Rectal Exam. Available at http://en.wikipedia.org/wiki/File:Digital_rectal_exam_nci-vol-7136-300.jpg
USPSTF Prostate Screening. Available at http://www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm Accessed March 20, 2013.
Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228-1235. Abstract
Brown CT, Yap T, Cromwell DA, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. Br Med J. 2007;334:25-28. Abstract
Van Kerrebroeck P, Steers W, Haab F. Establishing effective treatment of overactive bladder symptoms in men. Eur Urol. 2005;4(suppl):61.
Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006;60:959-966. Abstract
Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68:328-332. Abstract
Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the treatment of non-neurogenic male LUTS. European Association of Urology, 2011. http://guideline.gov/content.aspx?id=34066. Accessed April 2, 2013.
Terazosin [package insert]. Abbott Park, IL: Abbott Laboratories; 2003.
Doxazosin [package insert]. New York, NY: Pfizer Inc; 2003.
Tamsulosin [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2006.
Alfuzosin [package insert]. New York, NY: Sanofi-Synthelabo Inc; 2004.
Sildosin prescribing information. Morristown, NJ: Watson; 2008.
MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008;83:1002-1010. Abstract
Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur Urol. 2009;56:534-543. Abstract
Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to a-blocker treated men with residual urgency and frequency. J Urol. 2009;182:2825-2830. Abstract
Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res. 2008;20(suppl 3):S19-S26. Abstract
Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2003;44:695-700. Abstract
Roehrborn CG. Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia. Rev Urol. 2005;7(suppl 8):S43–S51.
Mochtar CA, Kiemeney LA, Laguna MP, et al. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology. 2005;65:300-305. Abstract
McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostate Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398. Abstract
Roehrborn CG, Siami P, Barkin J, et al; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131. Abstract
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinley JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61. Abstract
Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228-1234. Abstract
Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994-1003. Abstract
Cholhan HJ. Voiding Efficiency: A New Method Assessing Bladder Function [abstract 124]. Presented at: 32nd Annual Scientific Meeting of the American Urogynecologic Society; September 14-17, 2011; Providence, RI.

CME/CE

Overactive Bladder, Benign Prostatic Hyperplasia, or Something Else? Applying Treatment Algorithms

Authors: Claus Roehrborn, MD
CME/CE Released: 4/30/2013
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/30/2014

Target Audience and Goal Statement

This activity is intended for primary care physicians, urologists, diabetologists, endocrinologists, nurses, and nurse practitioners.

The goal of this activity is to facilitate effective dialogue between clinicians and patients, leading to "convergence" -- the aligning of different perspectives, understanding, and knowledge to focus on a common goal, ultimately driving more open, supported, and collaborative clinician-patient interactions -- to increase the identification and diagnosis of sexual health concerns during routine office visits with male patients, and facilitate development of a care plan that encompasses treatment of the sexual health symptom as well as any underlying medical or comorbid conditions.

Upon completion of this activity, participants will be able to:

Differentiate LUTS associated with BPH from those associated with OAB in a patient presenting with abnormal urination or voiding pattern
Integrate simple screening questions about urinary flow and arc into routine office visits
Select appropriate pharmacologic and nonpharmacologic management strategies in the care of patients diagnosed with LUTS associated with BPH vs those typical for OAB

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Claus Roehrborn, MD

Professor and Chair, Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas

Disclosures

Disclosure: Claus Roehrborn, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: GlaxoSmithKline; Lilly USA, LLC; ProArc Medical Ltd.; NxThera; Sophiris Bio Inc.; NeoTract, Inc.
Served as a speaker or a member of a speakers bureau for: GlaxoSmithKline; Lilly USA, LLC

Dr Roehrborn does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Roehrborn does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Emilie McCardell

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Emilie McCardell has disclosed no relevant financial relationships.

Men's Health Steering Committee

Matt T. Rosenberg, MD

Medical Director, Mid-Michigan Health Centers, Department of Family Practice, Allegiance Health Systems, Jackson, Michigan

Disclosures

Disclosure: Matt T. Rosenberg, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Astellas Pharma, Inc.; Ferring Pharmaceuticals; Horizon Pharma; Lilly USA, LLC; Pfizer Inc
Served as a speaker or member of a speakers bureau for: Astellas Pharma, Inc.; Forest Laboratories, Inc.; Horizon Pharma; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Pfizer Inc

David M. Albala, MD

Medical Director, Associated Medical Professionals; Chief of Urology, Crouse Hospital, Syracuse, New York

Disclosures

Disclosure: David M. Albala, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Titan Medical, Inc.
Served as a speaker or member of a speakers bureau for: GlaxoSmithKline
Owns stock, stock options, or bonds from: Applied Medical Resources Corporation

Culley C. Carson III, MD

Rhodes Distinguished Professor of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Disclosures

Disclosure: Culley C. Carson III, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Auxilium Pharmaceuticals, Inc.; Lilly USA, LLC; GlaxoSmithKline; American Medical Systems, Inc.
Served as a speaker or member of a speakers bureau for: Auxilium Pharmaceuticals, Inc.; Lilly USA, LLC; GlaxoSmithKline; American Medical Systems, Inc.
Received grants for clinical research from: Auxilium Pharmaceuticals, Inc.; Lilly USA, LLC; GlaxoSmithKline; American Medical Systems, Inc.

Sheryl Kingsberg, MD

Professor, Departments of Reproductive Biology and Psychiatry, Case Western Reserve University School of Medicine; Chief, Division of Behavioral Medicine, Department of Obstetrics and Gynecology, University Hospitals MacDonald Women's Hospital, Cleveland, Ohio

Disclosures

Disclosure: Sheryl Kingsberg, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BioSante Pharmaceuticals, Inc.; Pfizer Inc; Shionogi & Co., Ltd.; Sanofi; Trimel Pharmaceuticals; Palatin Technologies, Inc.; Novo Nordisk
Owns stock, stock options, or bonds from: Viveve

Martin M. Miner, MD

Clinical Associate Professor of Family Medicine and Urology, Brown University; Co-director, Men’s Health Center, The Miriam Hospital, Providence, Rhode Island

Disclosures

Disclosure: Martin M. Miner, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck & Co., Inc.
Received grants for clinical research from: Auxilium Pharmaceuticals, Inc.; Forest Laboratories, Inc.

David R. Staskin, MD

Associate Professor of Urology, Tufts University School of Medicine, Boston, Massachusetts

Disclosures

Disclosure: David R. Staskin, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Antares Pharma Inc.; Astellas Pharma, Inc.; Takeda Pharmaceuticals North America, Inc.; TheraVida, Inc.
Served as a speaker or member of a speakers bureau for: Allergan, Inc.; Astellas Pharma, Inc.; Watson Pharmaceuticals, Inc.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Nurse Planner

Laurie E. Scudder, DNP, NP

Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

Disclosures

Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For Nurses

Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Accredited status does not imply endorsement by Medscape, LLC or ANCC of any commercial products discussed in conjunction with the educational activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Family Medicine

CME/CE

Overactive Bladder, Benign Prostatic Hyperplasia, or Something Else? Applying Treatment Algorithms

Authors: Claus Roehrborn, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME/CE Released: 4/30/2013

Valid for credit through: 4/30/2014

processing....

This feature requires the newest version of Flash. You can download it here.

CME/CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Author(s)

Claus Roehrborn, MD

Editor(s)

Emilie McCardell

Men's Health Steering Committee

Matt T. Rosenberg, MD

David M. Albala, MD

Culley C. Carson III, MD

Sheryl Kingsberg, MD

Martin M. Miner, MD

David R. Staskin, MD

CME Reviewer(s)

Nafeez Zawahir, MD

Nurse Planner

Laurie E. Scudder, DNP, NP

Peer Reviewer

CME/CE

Overactive Bladder, Benign Prostatic Hyperplasia, or Something Else? Applying Treatment Algorithms

Target Audience and Goal Statement

Disclosures

Author(s)

Claus Roehrborn, MD

Editor(s)

Emilie McCardell

Men's Health Steering Committee

Matt T. Rosenberg, MD

David M. Albala, MD

Culley C. Carson III, MD

Sheryl Kingsberg, MD

Martin M. Miner, MD

David R. Staskin, MD

CME Reviewer(s)

Nafeez Zawahir, MD

Nurse Planner

Laurie E. Scudder, DNP, NP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Overactive Bladder, Benign Prostatic Hyperplasia, or Something Else? Applying Treatment Algorithms